Risk of impairment of investment interests in alliance medical corporations
First written in FY2020. 3 of 8 entries say "Materialised", first in FY2021-Q3. Latest entry: FY2025.
The whole theme swung hardest in 2017: 8 of 25 companies on the "Worse" side.
- FY2025WorsenedAnnual report
「Extraordinary losses included ¥0 million in losses on disposal of fixed assets, ¥5 million in impairment losses on investments, and ¥9 million in dismantling costs.」
An impairment loss on investments of ¥5 million was recognized, indicating that loss recognition due to impairment of investment interests in the medical-related business and other areas is continuing. - FY2024-Q1MaterialisedAnnual report
「Impairment loss on investments - 1」
An impairment loss on investments of ¥1 million was recognized as an extraordinary loss during the first quarter of the current consolidated fiscal year. - FY2023-Q3MitigatedAnnual report
「For the fiscal year ending September 2022, we recognized quarterly net income attributable to owners of the parent of ¥369 million, compared with quarterly net income attributable to owners of the parent of ¥120 million in the same period of the previous year. Accordingly, we recognized an equity-method investment gain of ¥108 million, equivalent to our 29.5% ownership interest, for the nine months ended September 2022, compared with an equity-method investment gain of ¥35 million in the same period of the previous year.」
As DAホールディングス' profit increased, our equity-method investment gain also increased from ¥35 million in the same period of the previous year to ¥108 million. - FY2023-Q2MitigatedAnnual report
「For the fiscal year ending June 2022, we recognized interim net income attributable to owners of the parent of ¥364 million, compared with interim net income attributable to owners of the parent of ¥131 million in the previous fiscal year. Accordingly, we recognized an equity-method investment gain of ¥107 million, equivalent to our 29.5% ownership interest, for the nine months ended December 2021, compared with an equity-method investment gain of ¥38 million in the same period of the previous year.」
DAホールディングス' interim net income increased from ¥131 million to ¥364 million, while our equity-method investment gain increased from ¥38 million to ¥107 million. - FY2022MitigatedAnnual report
「Accordingly, we recognized an equity-method investment gain of ¥35 million, equivalent to our 29.5% ownership interest, for the consolidated fiscal year, compared with an equity-method investment loss of ¥287 million in the same period of the previous year.」
As the performance of DAホールディングス recovered, the equity-method investment loss of ¥287 million in the previous year turned into an investment gain of ¥35 million in the current year. - FY2021MaterialisedAnnual report
「Mainly due to an impairment loss on investments in the medical-related business, we recognized a net loss attributable to owners of the parent of ¥975 million for the fiscal year ended December 2020. Accordingly, we recognized an equity-method investment loss of ¥287 million, equivalent to our 29.5% ownership interest, in the consolidated fiscal year.」
An equity-method investment loss of ¥287 million was actually recognized in connection with the risk of impairment of investment interests in alliance partners and others. - FY2021-Q3MaterialisedAnnual report
「In accordance with the new receivables management policy, an impairment loss on investments of ¥48 million in a foundation for a general incorporated association included in the hospital-related business has been recognized as an extraordinary loss on a year-to-date basis.」
An actual impairment loss on investments of ¥48 million was recognized in connection with the impairment of investment interests and foundations related to alliance partners and others. - FY2020First statedAnnual report
「The Group may hold investment interests in medical corporations with which it has alliances. These investment interests may be impaired if the operating conditions of an alliance medical corporation deteriorate or for other reasons.」
The risk of impairment of investment interests held in alliance medical corporations was newly disclosed separately.